Incruse Ellipta FDA Approval History
Incruse Ellipta (umeclidinium) is an anticholinergic bronchodilator indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD).
Development Timeline for Incruse Ellipta
|May 1, 2014||FDA Approves Incruse Ellipta (umeclidinium) for the Treatment of COPD|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.